However, the PGE2 addition to Regorafenib treated HMEG cells could not further increase the Bcl-2 expression in tumor cells, indicating that the Regorafenib-induced Bcl-2-upregulation seen in the tumor cells represents a COX2-PGE2 independent tumor cell-autonomous resistance mechanism. Here, BCL2 is linked to neoplasm.